Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model
— BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse — — Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder — — A brief virtual presentation discussing the findings is scheduled for Monday, March 15th at 11am ET — VANCOUVER, British…
